You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 29, 2024

CLINICAL TRIALS PROFILE FOR MECHLORETHAMINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for mechlorethamine hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002462 ↗ RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1989-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease.
NCT00002463 ↗ Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed National Cancer Institute (NCI) Phase 2 1989-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
NCT00002463 ↗ Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed M.D. Anderson Cancer Center Phase 2 1989-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
NCT00002714 ↗ Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease Completed National Cancer Institute (NCI) Phase 2 1995-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease.
NCT00002714 ↗ Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease Completed Stanford University Phase 2 1995-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease.
NCT00002715 ↗ Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 1989-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for mechlorethamine hydrochloride

Condition Name

Condition Name for mechlorethamine hydrochloride
Intervention Trials
Lymphoma 9
Mycosis Fungoides 5
Cutaneous T-cell Lymphoma 2
Hodgkin Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for mechlorethamine hydrochloride
Intervention Trials
Lymphoma 13
Hodgkin Disease 12
Mycoses 6
Mycosis Fungoides 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for mechlorethamine hydrochloride

Trials by Country

Trials by Country for mechlorethamine hydrochloride
Location Trials
United States 84
Canada 9
United Kingdom 4
Italy 3
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for mechlorethamine hydrochloride
Location Trials
California 7
New York 6
Illinois 5
Pennsylvania 4
Texas 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for mechlorethamine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for mechlorethamine hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 13
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for mechlorethamine hydrochloride
Clinical Trial Phase Trials
Completed 8
Unknown status 5
Active, not recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mechlorethamine hydrochloride

Sponsor Name

Sponsor Name for mechlorethamine hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 5
Yaupon Therapeutics 2
European Organisation for Research and Treatment of Cancer - EORTC 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for mechlorethamine hydrochloride
Sponsor Trials
Other 20
Industry 9
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.